Tacrolimus Ointment for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Tacrolimus Ointment for Health & Longevity

Created on 09/20/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A non-steroid anti-inflammatory ointment that does not thin skin, so it can be used on the face, eyelids and body folds over long periods. Eczema evidence is strongest: twice-weekly application after the rash clears keeps flares away for months. Vitiligo and painful mouth lesions sit outside the approved use. First-week burning is common; the cancer warning is unresolved. (Full Review)

Protocol

Standard induction regimen
Thin layer twice daily
To affected skin only, the smallest amount that controls signs, until clearance
Proactive maintenance regimen
Twice weekly after clearance
To sites that previously flared, for up to 12 months
Strength selection
0.1% for adults
0.03% for children aged 2 to 15 and for adult facial skin
Time to effect
Full eczema response
3 to 6 weeks
Itch and redness improve within 3 days
Vitiligo repigmentation
6 months
Face and neck respond far better than hands and feet
Facial psoriasis
Day 8
Separation from the ointment base alone

Benefits

Contraindications
  • Immunocompromised adults and children (systemic immunosuppression, untreated HIV)
  • Known hypersensitivity to tacrolimus or any ointment component
  • Pre-malignant or malignant skin lesion at the site (suspected cutaneous T-cell lymphoma)
  • Barrier-defect disease (Netherton syndrome, lamellar ichthyosis, erythroderma, graft-versus-host)
  • Children under 2 years of age
  • Active untreated bacterial or viral skin infection at the site
  • Pregnant and breastfeeding women
  • Ultraviolet therapy and tanning on the same skin (narrowband ultraviolet B, psoralen plus ultraviolet A)
    •
Key Interactions
  • CYP3A4 inhibitors, prescription (erythromycin, clarithromycin, itraconazole, ketoconazole, fluconazole, ritonavir, diltiazem, verapamil)
  • Cimetidine, over-the-counter
  • Alcohol, including over-the-counter alcohol-containing preparations
  • Grapefruit juice and grapefruit-containing supplements
  • St John's wort supplements
  • Turmeric, curcumin and schisandra supplements
  • Additive local immunosuppressants (topical corticosteroids, topical pimecrolimus, topical ruxolitinib)
    •

Risk & Side Effects

  • High: Application-site burning, stinging and itching; alcohol-induced facial flushing; folliculitis and acneiform eruptions; transient flu-like symptoms and headache
    •
  • Medium: Localized herpes viral reactivation; lymph node enlargement requiring investigation
    •
  • Low: Lymphoma and skin cancer signal; rosaceiform and granulomatous facial dermatitis; systemic absorption where the skin barrier is severely broken
    •
  • Speculative: Accelerated ultraviolet-induced skin tumor formation
    •

Monitoring

Marker Target Why
Whole-blood tacrolimus trough Below 2 ng/mL, ideally undetectable Confirms exposure stays cutaneous
Estimated glomerular filtration rate Above 90 mL/min/1.73 m² Calcineurin inhibition constricts renal vessels if absorbed
Serum creatinine 0.7 to 1.0 mg/dL in men, 0.6 to 0.9 mg/dL in women Direct input to the filtration estimate
Serum potassium 4.0 to 4.5 mmol/L Systemic tacrolimus raises potassium
Total serum immunoglobulin E Below 100 IU/mL Marks atopic drive and predicts who holds remission on twice-weekly dosing
Transepidermal water loss Below roughly 15 g/m²/h at previously affected sites Objective barrier recovery, which tracks flare risk in visually clear skin
25-hydroxyvitamin D 40 to 60 ng/mL Low status tracks with atopic dermatitis severity

Cadence: Response at 2 weeks and 6 weeks, then every 3 to 6 months while maintenance dosing continues; annual kidney markers for large-area users

Qualitative Assessment

  • Itch intensity on waking, rated 0 to 10, which moves before visible signs do
  • Nights per week with scratch-disturbed sleep
  • Duration of application-site burning, which should shorten week on week
  • Flare frequency and the number of days per month needing rescue treatment
  • Skin texture at previously lichenified sites, specifically loss of thickening rather than loss of redness
  • Confidence in going without a topical corticosteroid on facial skin
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.